Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Maze Therapeutics, Inc.NASDAQ: MAZE

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $12.41M rose 58.6% year over year, ahead of the +38.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 10 analysts of $15.79M (-54.2%) for the fiscal year ending Dec 2026, a slowdown from the +30.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.41M+18.3% QoQ
Last fiscal yearDec 2025
$34.45M+30.4% YoY
LTMMar 2026
$39.04M+38.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.6%-73.0%-131.7 pp
1 year+30.4%-54.2%-84.6 pp
3-year CAGR+14.7%-38.6%-53.3 pp
5-year CAGR+35.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
34.45M USD
Year-over-year change
+30.4%
3-year CAGR
+14.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +38.9% is the 2nd highest of 8, against a peer median of +23.4%.
  • Selling, general & admin amounts to 195.2% of revenue for MAZE, versus a peer median of 70.6%.
MAZE Competitors
Selling, General & Admin for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$376.47M USD+23.4%+19.5%57.8%
ARDXArdelyx, Inc.LTM Mar 2026$356.28M USD+23.3%+63.9%83.3%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$351.33M USD+8.3%+2.1%34.8%
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$39.04M USD+38.9%+14.7%195.2%
SEPNSepterna, Inc.LTM Sep 2026$36.57M USD+38.0%—38.0%
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M USD+21.7%+16.7%—
Peer median (excluding MAZE) —+23.4%+31.4%70.6%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.